Login
$CTNM
$9.67 -$0.19 (1.93%) Live

$CTNM SEC Filings

Filed On Filing
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 SCHEDULE 13G
04 Nov 2026 144
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

SAN DIEGO – November 3, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases w...

28 Oct 2026 SCHEDULE 13G
28 Oct 2026 SCHEDULE 13G/A
22 Oct 2026 SCHEDULE 13G
01 Oct 2026 144
14 Sep 2026 8-K: Other Events

–Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint

08 Sep 2026 Form 4: Stengone Carmine N., Director

Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($41.1K)

08 Sep 2026 144
01 Sep 2026 144
14 Aug 2026 SCHEDULE 13G/A
03 Aug 2026 Form 4: Stengone Carmine N., Director

Received 2,500 shares by exercise or conversion ($2.53K) · Sold 2,500 shares ($40K)

03 Aug 2026 144
03 Aug 2026 144
30 Jul 2026 10-Q
30 Jul 2026 8-K: Results of Operations and Financial Condition

SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with...

27 Jul 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support